Newly diagnosed GBM

​Trials listed below that do not have a blue link are not currently open to accrual


Protocol #

​Sponsor

​Title

OSU 12079 ​Celldex ​An International, Randomized, Double-Blind, Controlled Study of
Rindopepimut/GMCSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma

OSU 12094 ​NovoCure ​A Prospective, Multi-center Trial of NovoT T F-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM

 

​RTOG 0825 ​RTOG ​A Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma

 

​RTOG 0837 ​RTOG ​Randomized, Phase II, Double-Blind, Placebo-Controlled Trial of Conventional Chemoradiation and Adjuvant Temozolomide Plus Cediranib versus Conventional Chemoradiation and Adjuvant Temozolomide Plus Placebo in Patients with Newly Diagnosed Glioblastoma

 

​OSU 07059 ​Advantagene ​A Phase IIa Study of ADV-TK + Valacyclovir Gene Therapy in Combination with Standard Radiation Therapy for Malignant Gliomas

 

​OSU 13089 ​Plexxikon ​An Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination with Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

 




For more information, contact:

Jill Brown
Jill.Brown@osumc.edu
614-293-5554

   

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu